- Siamak Daneshmand, MD
Siamak Daneshmand, MD
- Associate Professor of Urology
- Director, Center for Urologic Oncology
- University of Southern California
- Jason A Efstathiou, MD, DPhil
Jason A Efstathiou, MD, DPhil
- Associate Professor of Radiation Oncology
- Harvard Medical School
- Associate Radiation Oncologist
- Massachusetts General Hospital
- Section Editors
- Jerome P Richie, MD, FACS
Jerome P Richie, MD, FACS
- Section Editor — Cancer of the Urethra, Penis, and Ureter; Urologic Surgery; Prostate Cancer
- Elliott Carr Cutler Professor of Surgery
- Harvard Medical School
- W Robert Lee, MD, MS, MEd
W Robert Lee, MD, MS, MEd
- Section Editor — Prostate Cancer
- Professor of Radiation Oncology
- Duke University Medical Center
Primary urethral carcinomas are rare but aggressive tumors that account for less than 1 percent of all genitourinary malignancies. Urethral cancer is not one malignancy but a spectrum of diseases with various histologies. The approach to management and prognosis depends upon gender, location of the tumor within the urethra, and extent of disease.
This topic will discuss the clinical presentation, evaluation, and treatment of urethral cancer.
An analysis from the Surveillance, Epidemiology, and End Results (SEER) database included 1075 men and 540 women with urethral cancer . The age-adjusted incidence rate was 4.3 and 1.5 per million in men and women, respectively. The incidence increased with age, with a maximum of 32 per million in men and 9.5 per million in women aged 75 to 84 years. In addition to the higher incidence in men, urethral cancer was also approximately twice as common in African Americans as compared with Whites.
A European study from the RARECARE project identified 1059 cases over a seven-year period and estimated that there are approximately 650 new cases per year in the European Union . The age-standardized rates were 1.6 and 0.6 per million in men and women, respectively.
Although the etiology of urethral cancer is not well understood, factors that have been associated with urethral cancer include:
- Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology 2006; 68:1164.
- Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 2012; 48:456.
- McMillan A, Pakianathan M, Mao JH, Macintyre CC. Urethral stricture and urethritis in men in Scotland. Genitourin Med 1994; 70:403.
- Park S, McAninch JW. Straddle injuries to the bulbar urethra: management and outcomes in 78 patients. J Urol 2004; 171:722.
- Kaplan GW, Bulkey GJ, Grayhack JT. Carcinoma of the male urethra. J Urol 1967; 98:365.
- Raghavaiah NV. Radiotherapy in the treatment of carcinoma of the male urethra. Cancer 1978; 41:1313.
- Herr HW. Surgery of Penile and Urethral Carcinoma. In: Campbell's Urology, 7th, Walsh PC, Retik AB, Vaughan ED, et al (Eds), WB Saunders, 1998. p.3401.
- Rajan N, Tucci P, Mallouh C, Choudhury M. Carcinoma in female urethral diverticulum: case reports and review of management. J Urol 1993; 150:1911.
- Thomas AA, Rackley RR, Lee U, et al. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol 2008; 180:2463.
- Wiener JS, Walther PJ. A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 1994; 151:49.
- Eng TY, Naguib M, Galang T, Fuller CD. Retrospective study of the treatment of urethral cancer. Am J Clin Oncol 2003; 26:558.
- Wiener JS, Liu ET, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res 1992; 52:5018.
- Carroll PR, Dixon CM. Surgical anatomy of the male and female urethra. Urol Clin North Am 1992; 19:339.
- Rabbani F. Prognostic factors in male urethral cancer. Cancer 2011; 117:2426.
- Sharp DS, Angermeier KW. Tumors of the Urethra. In: Campbell-Walsh Urology, 11th ed, Wein AJ, Kavoussi LR, Partin AW, Peters C (Eds), 2016. p.4.
- Wein AJ, Kavoussi LR, Partin AW, Peters CA. Tumors of the Urethra. In: Campbell-Walsh Urology, 11th ed, Elsevier, 2016. p.880.
- Hopkins SC, Nag SK, Soloway MS. Primary carcinoma of male urethra. Urology 1984; 23:128.
- Dodson MK, Cliby WA, Keeney GL, et al. Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen. Gynecol Oncol 1994; 55:304.
- Murphy DP, Pantuck AJ, Amenta PS, et al. Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. J Urol 1999; 161:1881.
- Reis LO, Billis A, Ferreira FT, et al. Female urethral carcinoma: evidences to origin from Skene's glands. Urol Oncol 2011; 29:218.
- Vapnek JM, Hricak H, Carroll PR. Recent advances in imaging studies for staging of penile and urethral carcinoma. Urol Clin North Am 1992; 19:257.
- Anderson KA, McAninch JW. Primary squamous cell carcinoma of anterior male urethra. Urology 1984; 23:134.
- Stewart SB, Leder RA, Inman BA. Imaging tumors of the penis and urethra. Urol Clin North Am 2010; 37:353.
- Kim B, Kawashima A, LeRoy AJ. Imaging of the male urethra. Semin Ultrasound CT MR 2007; 28:258.
- Touijer AK, Dalbagni G. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology 2004; 63:33.
- Cohen MS, Triaca V, Billmeyer B, et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol 2008; 179:536.
- Dalbagni G, Donat SM, Eschwège P, et al. Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166:1759.
- Konnak JW. Conservative management of low grade neoplasms of the male urethra: a preliminary report. J Urol 1980; 123:175.
- Salgado CJ, Monstrey S, Hoebeke P, et al. Reconstruction of the penis after surgery. Urol Clin North Am 2010; 37:379.
- Koontz BF, Lee WR. Carcinoma of the urethra: radiation oncology. Urol Clin North Am 2010; 37:459.
- Moinuddin Ali M, Klein FA, Hazra TA. Primary female urethral carcinoma. A retrospective comparison of different treatment techniques. Cancer 1988; 62:54.
- Kuettel MR, Parda DS, Harter KW, et al. Treatment of female urethral carcinoma in medically inoperable patients using external beam irradiation and high dose rate intracavitary brachytherapy. J Urol 1997; 157:1669.
- Johnson DE, O'Connell JR. Primary carcinoma of female urethra. Urology 1983; 21:42.
- Prempree T, Amornmarn R, Patanaphan V. Radiation therapy in primary carcinoma of the female urethra. II. An update on results. Cancer 1984; 54:729.
- Weghaupt K, Gerstner GJ, Kucera H. Radiation therapy for primary carcinoma of the female urethra: a survey over 25 years. Gynecol Oncol 1984; 17:58.
- Sharma DN, Gandhi AK, Bhatla N, et al. High-dose-rate interstitial brachytherapy for female peri-urethral cancer. J Contemp Brachytherapy 2016; 8:41.
- Garden AS, Zagars GK, Delclos L. Primary carcinoma of the female urethra. Results of radiation therapy. Cancer 1993; 71:3102.
- Baskin LS, Turzan C. Carcinoma of male urethra: management of locally advanced disease with combined chemotherapy, radiotherapy, and penile-preserving surgery. Urology 1992; 39:21.
- Licht MR, Klein EA, Bukowski R, et al. Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra. J Urol 1995; 153:1918.
- Kent M, Zinman L, Girshovich L, et al. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol 2015; 193:532.
- Gakis G, Morgan TM, Daneshmand S, et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol 2015; 26:1754.
- Dinney CP, Johnson DE, Swanson DA, et al. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology 1994; 43:506.
- Ray B, Canto AR, Whitmore WF Jr. Experience with primary carcinoma of the male urethra. J Urol 1977; 117:591.
- Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65:433.
- Gakis G, Morgan TM, Efstathiou JA, et al. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol 2016; 34:97.
- Champ CE, Hegarty SE, Shen X, et al. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology 2012; 80:374.
- Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82:835.
- VanderMolen LA, Sheehy PF, Dillman RO. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest 2002; 20:206.
- Mitra AP, Alemozaffar M, Harris BN, et al. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology 2014; 84:1420.
- Hrbáček J, Macek P, Ali-El-Dein B, et al. Treatment and outcomes of urethral recurrence of urinary bladder cancer in women after radical cystectomy and orthotopic neobladder: a series of 12 cases. Urol Int 2015; 94:45.
- Stein JP, Hertz J, Nichols PW. Urethral recurrence in a woman after continent orthotopic urinary diversion for bladder cancer. Urology 2008; 71:755.e1.
- RISK FACTORS
- ANATOMY AND HISTOLOGY
- CLINICAL PRESENTATION
- General approach
- - Men
- - Women
- Radiation therapy
- Neoadjuvant and adjuvant chemotherapy
- Role of lymphadenectomy
- Adjuvant radiation therapy
- SURVEILLANCE FOLLOWING TREATMENT
- TREATMENT OF RECURRENT OR METASTATIC DISEASE
- SUMMARY AND RECOMMENDATIONS